This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Skin Disease, Burns and Wound Care



December 2017

Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs

Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking an important molecule in inflammation from a process which allows the body’s immune cells (specifically T-cells) to activate other immune cells and release substances which cause inflammation (cytokines).


December 2017

Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis

Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking a specific process which allows the body’s immune cells (specifically T-cells) from attacking and damaging the skin.


October 2017

Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus

  The treatment, rexmyelocel-T, is being developed to relieve leg pain at rest and heal leg ulcers. The treatment uses cells from bone marrow which are injected into the damaged blood vessel, where they restore existing blood vessels and create new blood vessels. By improving the blood flow in the limb, this treatment aims to …


April 2017

Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults

Certolizumab pegol is an anti-TNF (anti-tumour necrosis factor) drug. It works by blocking the action of TNF protein and which reduces inflammation. It is currently licensed for the treatment of several chronic inflammatory conditions, including Crohn’s Disease, rheumatoid arthritis, psoriatic arthritis and juvenile arthritis. If licensed for chronic plaque psoriasis in adults it will offer …


January 2017

Afamelanotide 16mg Implant (SCENESSE) for generalised vitiligo – first line in combination with narrow-band ultraviolet B light

Afamelanotide is a new drug to treat generalised vitiligo. Vitiligo is a long-term condition where white patches develop on the skin, because of a lack of pigment in the skin. This condition may cause significant psychological distress. Afamelanotide is administered as an implant once every 28 days with NB-UVB light therapy administered 2-3 times per …


September 2016

Cryopreserved human placental tissue (Stravix) for wound repair

Cryopreserved human placental tissue is a new treatment to aid the healing of wounds that may reduce inflammation and scarring. Skin damage through cuts, burns or surgery are a source of discomfort, inflammation and scarring, and can also lead to infections. Cryopreserved human placental tissue includes molecules and materials expected to aid wound healing as …


July 2016

Dupilumab for moderate to severe atopic dermatitis – second line

Dupilumab is a new injection for the treatment of atopic dermatitis. Some studies have suggested that dupilumab can help treat the symptoms of moderate to severe atopic dermatitis that is not responding to treatment with ointments or creams.


May 2016

Botulinum toxin A (Dysport) for hyperhidrosis of the axillae

Hyperhidrosis is the medical term for excessive sweating, most commonly affecting the palms of the hands, soles of the feet and the axillae (armpits). Although hyperhidrosis is not life-threatening, it increases the risk of skin infections and has a significant impact on the quality of life of those affected. Botulinum toxin A is a treatment …


April 2016

Crisaborole for adults, adolescents and children with atopic dermatitis

Atopic dermatitis, also known as eczema, is a long term condition that affects the skin. People with atopic dermatitis have sore, dry skin that causes intense itching, which can ooze and weep. This can lead to skin infections and trouble sleeping. It usually starts in infancy and can sometimes last into adulthood. Crisaborole is a …


March 2016

Allantoin (Zorblisa) for lesions associated with epidermolysis bullosa – first line

Epidermolysis bullosa is a rare inherited disease. The disease causes blistering, cuts and scarring of the skin which can vary from mild symptoms only, to severe disease causing disability or even death. At the moment there is no cure for epidermolysis bullosa and patients currently use wound care, bandages, and drug treatments to try and …

Get Alerts